Structure Therapeutics (NASDAQ: GPCR), a Bay Area biotech advancing next-gen oral obesity drugs, is emerging as the next top takeover target for Big Pharma.
Why it matters: Obesity drugs are reshaping biopharma dealmaking as major companies look to replace expiring patents and buy into a fast-growing market.
